Article abstract


Nature Medicine 15, 641 - 648 (2009)
Published online: 24 May 2009 | doi:10.1038/nm.1965

Toll-like receptor 2 ligands on the staphylococcal cell wall downregulate superantigen-induced T cell activation and prevent toxic shock syndrome

Thu A Chau1, Michelle L McCully1,2, William Brintnell3, Gary An4, Katherine J Kasper2, Enrique D Vinés2, Paul Kubes5, S M Mansour Haeryfar2, John K McCormick2,6, Ewa Cairns2,3, David E Heinrichs2 & Joaquín Madrenas1,2,3


Staphylococcal superantigens are pyrogenic exotoxins that cause massive T cell activation leading to toxic shock syndrome and death. Despite the strong adaptive immune response induced by these toxins, infections by superantigen-producing staphylococci are very common clinical events. We hypothesized that this may be partly a result of staphylococcal strains having developed strategies that downregulate the T cell response to these toxins. Here we show that the human interleukin-2 response to staphylococcal superantigens is inhibited by the simultaneous presence of bacteria. Such a downregulatory effect is the result of peptidoglycan-embedded molecules binding to Toll-like receptor 2 and inducing interleukin-10 production and apoptosis of antigen-presenting cells. We corroborated these findings in vivo by showing substantial prevention of mortality after simultaneous administration of staphylococcal enterotoxin B with either heat-killed staphylococci or Staphylococcus aureus peptidoglycan in mouse models of superantigen-induced toxic shock syndrome.

Top
  1. The FOCIS Centre for Clinical Immunology and Immunotherapeutics, Robarts Research Institute, London, Ontario, Canada.
  2. Department of Microbiology and Immunology, The University of Western Ontario, London, Ontario, Canada.
  3. Department of Medicine, The University of Western Ontario, London, Ontario, Canada.
  4. Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  5. Department of Physiology and Biophysics, University of Calgary, Calgary, Alberta, Canada.
  6. Lawson Health Research Institute, London, Ontario, Canada.

Correspondence to: Joaquín Madrenas1,2,3 e-mail: madrenas@robarts.ca



MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Will therapeutic peptides be kryptonite for superantigens?

Nature Medicine News and Views (01 Apr 2000)

Staphylococcal protein A inflames the lungs

Nature Medicine News and Views (01 Aug 2004)


Extra navigation

Subscribe to Nature Medicine

Subscribe

Open Innovation Challenges

naturejobs

ADVERTISEMENT